Xing Bao-cai, Yuan Yan-hua, Hu Zhi-guo, Liu Yue-xiang, Han Yan, Liu Nian, Chen Wei-feng, Wang Yu
Department of Biliary Surgery, Cancer Biological Therapy and Diagnosis Center, Beijing Cancer Hospital, Beijing 100036, China.
Zhonghua Yi Xue Za Zhi. 2004 Dec 2;84(23):1980-2.
To investigate the potential of utilizing NY-ESO-1/LAGE-1 antigens in hepatocellular carcinoma (HCC) vaccines.
RT-PCR method was used to detect the expression of NY-ESO-1/LAGE-1 mRNA in the cancerous tissues and adjacent tissues resected from 34 patients with HCC. ELISA assay was adopted to analyze the NY-ESO-1 specific antibodies in 37 serum samples of HCC patients, 1 positive control sample, and 8 samples of normal persons.
Nine (26.5%) out of the 34 HCC samples were NY-ESO-1 mRNA positive, while 12 (35.3%) were LAGE-1 positive. Among them, seven HCC samples expressed both genes, and 14 (41.6%) expressed at least one of the genes. Among the 37 serum samples tested six contained high titer of anti-NY-ESO-1 antibodies. Five of the samples were from stage III or later stage HCC patients; one was from a stage II patient.
NY-ESO-1/LAGE-1 mRNA is expressed in a high frequency in HCC tissue samples, and induces autologous humoral responses in HCC patients. Both of the antigens can be considered as candidates for HCC vaccines.
探讨在肝细胞癌（HCC）疫苗中利用NY-ESO-1/LAGE-1抗原的可能性。
采用逆转录聚合酶链反应（RT-PCR）法检测34例HCC患者癌组织及癌旁组织中NY-ESO-1/LAGE-1 mRNA的表达。采用酶联免疫吸附测定（ELISA）法分析37例HCC患者血清样本、1份阳性对照样本及8份正常人样本中的NY-ESO-1特异性抗体。
34例HCC样本中，9例（26.5%）NY-ESO-1 mRNA呈阳性，12例（35.3%）LAGE-1呈阳性。其中，7例HCC样本两种基因均表达，14例（41.6%）至少表达其中一种基因。在检测的37份血清样本中，6份含有高滴度抗NY-ESO-1抗体。其中5份样本来自III期或更晚期HCC患者；1份来自II期患者。
NY-ESO-1/LAGE-1 mRNA在HCC组织样本中高频率表达，并在HCC患者中诱导自身体液免疫反应。这两种抗原均可被视为HCC疫苗的候选抗原。
Zotero 插件